CN107648618B - 一种药物递送体系及其制备方法与应用 - Google Patents
一种药物递送体系及其制备方法与应用 Download PDFInfo
- Publication number
- CN107648618B CN107648618B CN201710891549.8A CN201710891549A CN107648618B CN 107648618 B CN107648618 B CN 107648618B CN 201710891549 A CN201710891549 A CN 201710891549A CN 107648618 B CN107648618 B CN 107648618B
- Authority
- CN
- China
- Prior art keywords
- moiety
- polypeptide
- assembly
- drug
- drug delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 230000004044 response Effects 0.000 claims abstract description 31
- 229920001184 polypeptide Polymers 0.000 claims description 120
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 120
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 120
- 238000000034 method Methods 0.000 claims description 23
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 claims description 6
- 102000047934 Caspase-3/7 Human genes 0.000 claims description 6
- 108700037887 Caspase-3/7 Proteins 0.000 claims description 6
- 102100035716 Glycophorin-A Human genes 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 125000003827 glycol group Chemical group 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 5
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 48
- 229940079593 drug Drugs 0.000 abstract description 48
- 239000012216 imaging agent Substances 0.000 abstract description 32
- 239000002872 contrast media Substances 0.000 abstract description 7
- 230000014759 maintenance of location Effects 0.000 abstract description 5
- 239000002547 new drug Substances 0.000 abstract description 2
- 230000009466 transformation Effects 0.000 abstract description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 42
- 150000001413 amino acids Chemical group 0.000 description 39
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 239000011347 resin Substances 0.000 description 22
- 229920005989 resin Polymers 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 17
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 14
- 239000000758 substrate Substances 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002086 nanomaterial Substances 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- -1 polymerase Proteins 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000000502 dialysis Methods 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 8
- 239000002121 nanofiber Substances 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 239000003875 Wang resin Substances 0.000 description 7
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000006399 behavior Effects 0.000 description 6
- 238000009833 condensation Methods 0.000 description 6
- 230000005494 condensation Effects 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000001338 self-assembly Methods 0.000 description 6
- 238000010008 shearing Methods 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 description 5
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 238000010567 reverse phase preparative liquid chromatography Methods 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 102000005600 Cathepsins Human genes 0.000 description 3
- 108010084457 Cathepsins Proteins 0.000 description 3
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 3
- 108090000279 Peptidyltransferases Proteins 0.000 description 3
- 108010016555 SmacN7 peptide Proteins 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229920001427 mPEG Polymers 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000007669 thermal treatment Methods 0.000 description 3
- CYMADHGOEXFBSX-UHFFFAOYSA-N 1,4,7,10-tetrazacyclododecane-1,4,7,10-tetracarboxylic acid Chemical compound OC(=O)N1CCN(C(O)=O)CCN(C(O)=O)CCN(C(O)=O)CC1 CYMADHGOEXFBSX-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102100029855 Caspase-3 Human genes 0.000 description 2
- 108010065152 Coagulase Proteins 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 238000005411 Van der Waals force Methods 0.000 description 2
- 231100000439 acute liver injury Toxicity 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 108010078430 glutamine phenylacetyltransferase Proteins 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 230000003439 radiotherapeutic effect Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SEFVRKXJJPMVHQ-UHFFFAOYSA-N 2-[[2-[[2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]butanedioic acid Chemical compound NC(N)=NCCCC(NC(=O)CN)C(=O)NCC(=O)NC(CC(O)=O)C(O)=O SEFVRKXJJPMVHQ-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007626 photothermal therapy Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical class C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
Abstract
Description
Claims (4)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710891549.8A CN107648618B (zh) | 2017-09-27 | 2017-09-27 | 一种药物递送体系及其制备方法与应用 |
PCT/CN2017/106078 WO2019061561A1 (zh) | 2017-09-27 | 2017-10-13 | 一种药物递送体系及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710891549.8A CN107648618B (zh) | 2017-09-27 | 2017-09-27 | 一种药物递送体系及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107648618A CN107648618A (zh) | 2018-02-02 |
CN107648618B true CN107648618B (zh) | 2020-05-08 |
Family
ID=61116325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710891549.8A Active CN107648618B (zh) | 2017-09-27 | 2017-09-27 | 一种药物递送体系及其制备方法与应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN107648618B (zh) |
WO (1) | WO2019061561A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108949147B (zh) * | 2018-06-22 | 2021-02-09 | 国家纳米科学中心 | 一种分子影像探针及其应用 |
CN111603573B (zh) * | 2019-02-26 | 2022-11-15 | 国家纳米科学中心 | 一种spect分子影像探针及其制备方法和应用 |
CN110665016A (zh) * | 2019-10-25 | 2020-01-10 | 国家纳米科学中心 | 一种成像探针及其制备方法和应用 |
CN114075266A (zh) * | 2020-08-13 | 2022-02-22 | 国家纳米科学中心 | 一种用于光热治疗的多肽组装单体及其制备方法和应用 |
CN112370533B (zh) * | 2020-08-24 | 2022-09-13 | 长沙理工大学 | 一种能长时间成像fap的生物发光探针及其应用 |
CN112979731A (zh) * | 2021-02-18 | 2021-06-18 | 郑州大学 | 一种活体自组装mri成像探针及其制备方法和应用 |
CN112999348B (zh) * | 2021-03-31 | 2022-06-03 | 西南交通大学 | 一种形貌可变的多肽-染料偶联物及制备方法与应用 |
CN113397032B (zh) * | 2021-05-24 | 2023-03-10 | 江苏省农业科学院 | 基于牛蒡糖蛋白的营养素递送体系及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG149013A1 (en) * | 2003-12-17 | 2009-01-29 | Wyeth Corp | Immunogenic peptide carrier conjugates and methods of producing same |
WO2013036743A1 (en) * | 2011-09-09 | 2013-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Imaging agents for imaging protease activity and uses thereof |
CN104558107B (zh) * | 2013-10-09 | 2018-04-27 | 国家纳米科学中心 | 酶响应性的两亲性多肽和药物载体及其制备方法 |
CN104707150B (zh) * | 2013-12-11 | 2017-10-31 | 中国科学院上海药物研究所 | 肿瘤酶激活的量子点探针及其制备方法与用途 |
CN104894151A (zh) * | 2015-05-29 | 2015-09-09 | 扬州大学 | 一种刺激淋巴细胞活化的纳米基因药物及其制备方法 |
CN106084003B (zh) * | 2016-06-12 | 2019-06-25 | 国家纳米科学中心 | 基于细胞内酶催化聚合的多肽单体分子及其在构建纳米材料中的应用 |
CN106822036B (zh) * | 2016-12-15 | 2022-08-09 | 国家纳米科学中心 | 特异靶向多肽自组装纳米载体、载药纳米颗粒及制备方法 |
CN107137724B (zh) * | 2017-05-22 | 2020-11-10 | 国家纳米科学中心 | 一种细胞内构筑温度响应性聚集体的材料及其制备方法和应用 |
-
2017
- 2017-09-27 CN CN201710891549.8A patent/CN107648618B/zh active Active
- 2017-10-13 WO PCT/CN2017/106078 patent/WO2019061561A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2019061561A1 (zh) | 2019-04-04 |
CN107648618A (zh) | 2018-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107648618B (zh) | 一种药物递送体系及其制备方法与应用 | |
US10111963B2 (en) | Nanoparticle drug conjugates | |
Huang et al. | Synthesis and therapeutic applications of biocompatible or biodegradable hyperbranched polymers | |
ES2590679T3 (es) | Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre | |
US20110312877A1 (en) | Engineered tunable nanoparticles for delivery of therapeutics, diagnostics, and experimental compounds and related compositions for therapeutic use | |
JP2003531835A (ja) | ペプチドベースの化合物 | |
Ren et al. | Anticancer supramolecular hydrogel of D/L-peptide with enhanced stability and bioactivity | |
CN106729735B (zh) | 一种pH敏感的多肽聚合物及其制备方法和应用 | |
EP3459546A1 (en) | Multi-arm polymeric targeting anti-cancer conjugate | |
CN112972424B (zh) | 一种抗肿瘤多肽纳米药物及其制备方法和应用 | |
CN110665016A (zh) | 一种成像探针及其制备方法和应用 | |
US20070140972A1 (en) | Targeting compositions and preparation therof | |
CN108578369A (zh) | 表面双修饰的靶向人血清白蛋白纳米药物载体的制备与应用 | |
KR20190133252A (ko) | 멀티 암 표적 항암 콘쥬게이트 | |
CN108484733B (zh) | 双亲性靶向穿膜肽及其自组装的纳米探针、载药纳米颗粒 | |
CN102652836A (zh) | 靶向释药的抗癌蛋白质或多肽聚合物前药及其制备方法 | |
CN113069416B (zh) | 主动靶向型两亲性多肽复合纳米胶束前药及制备与应用 | |
CN111995745B (zh) | 一种双锁型聚合物及其制备方法和应用 | |
RU2519225C2 (ru) | Опосредующие транспорт коллоидные лекарственные соединения | |
Wu et al. | A new N-acetylgalactosamine containing peptide as a targeting vehicle for mammalian hepatocytes via asialoglycoprotein receptor endocytosis | |
Chen et al. | Dual fluorescence nano-conjugates based on gold nanoclusters for tumor-targeting imaging | |
CN110642968A (zh) | 双酶响应性哑铃形超两亲分子及其制备方法和用途 | |
CN111494641B (zh) | 肿瘤微环境响应性的表面电荷可反转纳米药物递送载体 | |
Kos et al. | Gene transfer with sequence-defined oligo (ethanamino) amides bioreducibly attached to a propylenimine dendrimer core | |
CN116712557A (zh) | EpCAM适配体靶向Dox透明质酸纳米凝胶及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230105 Address after: No. 2, Ruitai Road, Huangpu District, Guangzhou, Guangdong 510700 Patentee after: Acep (Guangzhou) Biotechnology Co.,Ltd. Address before: 100190 No. 11, north of Haidian District, Beijing, Zhongguancun Patentee before: NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230725 Address after: Room E302-04, Innovation Building, No. 29, Shengshengyuan Road, Life Science Park, Changping District, Beijing 102200 Patentee after: Aisaipu (Beijing) Biotechnology Co.,Ltd. Address before: No. 2, Ruitai Road, Huangpu District, Guangzhou, Guangdong 510700 Patentee before: Acep (Guangzhou) Biotechnology Co.,Ltd. |